
Nasus Pharma Ltd.: shareholders and insiders
Price
$2.70
November 18, 2026Market cap $24M
What Ploutos Investor adds for Nasus Pharma
Part of Ploutos Investor, €9.99 a month
- The full history in every section
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Mar 31, 2026 to Nov 16, 2026, from their own Form 4 filings.
Bought on the market
$61.8K
1 person
Sold on the market
–
nobody
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
- Jun 17, 2026Dan Benjamin TelemanChief Executive OfficerKind
- Apr 22, 2026Dan Benjamin TelemanChief Executive OfficerKind
- Mar 31, 2026Dan Benjamin TelemanChief Executive OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | Dan Benjamin TelemanChief Executive Officer | 6,550 | $3.10 | $20.3K | Form 4 | |
| Apr 22, 2026 | Dan Benjamin TelemanChief Executive Officer | 2,900 | $3.76 | $10.9K | Form 4 | |
| Mar 31, 2026 | Dan Benjamin TelemanChief Executive Officer | 15.0K | $2.04 | $30.6K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 22, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Udi GilboaShare of class21.1%
- Dr. Dalia MegiddoShare of class20.9%
- Dr. Ronnie Hershmanwith 1 more personShare of class15.3%
- Balyasny Asset Managementwith 4 more personsShare of class9.99%
- Balyasny Asset Management L.P.with 4 more personsShare of class9.99%
- Capital Point Ltd.Share of class6.35%
- Funicular Funds, LPwith 2 more personsShare of class5.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Udi Gilboa | 21.1% | 1.90M | Nov 10, 2025 | 13G | |
| Dr. Dalia Megiddo | 20.9% | 1.89M | Nov 12, 2025 | 13G | |
| Dr. Ronnie Hershmanwith 1 more person | 15.3% | 1.38M | Nov 13, 2025 | 13G | |
| Balyasny Asset Managementwith 4 more persons | 9.99% | 1.17M | Aug 14, 2026 | 13G/A | |
| Balyasny Asset Management L.P.with 4 more persons | 9.99% | 1.17M | May 15, 2026 | 13G | |
| Capital Point Ltd. | 6.35% | 575.1K | Aug 20, 2025 | 13G | |
| Funicular Funds, LPwith 2 more persons | 5.20% | 612.9K | Apr 7, 2026 | 13G |
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter
- Renaissance TechnologiesIn the quarter+20%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | – | – | 0.00% | |
| Renaissance Technologies | 14.6K | +20% | $100.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 0.89% of its shares outstanding were held short, +2.8% since the report before.
- Shares held short
- 80.4K
- 0.89%
- Since the report before78.2K on Sep 30, 2026
- +2.8%
- 4.7
- 17.2K
- Report date
- Oct 15, 2026
- Shares held short
- Aug 15, 2025: Shares held short 12.3K
- Aug 29, 2025: Shares held short 18.5K
- Sep 15, 2025: Shares held short 1,613
- Sep 30, 2025: Shares held short 22.1K
- Oct 15, 2025: Shares held short 11.2K
- Oct 31, 2025: Shares held short 4,158
- Nov 14, 2025: Shares held short 3,732
- Nov 28, 2025: Shares held short 3,063
- Dec 15, 2025: Shares held short 1,933
- Dec 31, 2025: Shares held short 5,300
- Jan 15, 2026: Shares held short 2,204
- Jan 30, 2026: Shares held short 4,385
- Feb 13, 2026: Shares held short 5,224
- Feb 27, 2026: Shares held short 8,874
- Mar 13, 2026: Shares held short 11.4K
- Mar 31, 2026: Shares held short 99.2K
- Apr 15, 2026: Shares held short 64.9K
- Apr 30, 2026: Shares held short 111.0K
- May 15, 2026: Shares held short 155.0K
- May 29, 2026: Shares held short 172.5K
- Jun 15, 2026: Shares held short 177.5K
- Jun 30, 2026: Shares held short 172.1K
- Jul 15, 2026: Shares held short 170.7K
- Jul 31, 2026: Shares held short 160.1K
- Aug 14, 2026: Shares held short 144.5K
- Aug 31, 2026: Shares held short 87.3K
- Sep 15, 2026: Shares held short 80.5K
- Sep 30, 2026: Shares held short 78.2K
- Oct 15, 2026: Shares held short 80.4K
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading52.9% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 52.9% of the shares in the reported trades were short sales, against 40.6% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 52.9%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 40.6%
- Change
- +12.3 pts
- Short sales a dayon average, of 7,098 shares
- 3,752
- More than atof 3,656 US-listed companies, same days
- 59%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 36.9%
- Oct 13, 2026: Short sales 43%
- Oct 14, 2026: Short sales 52.8%
- Oct 15, 2026: Short sales 7.6%
- Oct 16, 2026: Short sales 41.2%
- Oct 19, 2026: Short sales 37.5%
- Oct 20, 2026: Short sales 51.3%
- Oct 21, 2026: Short sales 83.9%
- Oct 22, 2026: Short sales 20%
- Oct 23, 2026: Short sales 30.1%
- Oct 26, 2026: Short sales 60%
- Oct 27, 2026: Short sales 19.5%
- Oct 28, 2026: Short sales 47.1%
- Oct 29, 2026: Short sales 41.2%
- Oct 30, 2026: Short sales 75%
- Nov 2, 2026: Short sales 45.5%
- Nov 3, 2026: Short sales 21.6%
- Nov 4, 2026: Short sales 7.1%
- Nov 5, 2026: Short sales 85%
- Nov 6, 2026: Short sales 76.8%
- Nov 9, 2026: Short sales 46.1%
- Nov 10, 2026: Short sales 49.2%
- Nov 11, 2026: Short sales 28.2%
- Nov 12, 2026: Short sales 77.5%
- Nov 13, 2026: Short sales 42.4%
- Nov 16, 2026: Short sales 55.5%
- Nov 17, 2026: Short sales 40.2%
- Nov 18, 2026: Short sales 26.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Dan Benjamin TelemanChief Executive OfficerDirectly163.5K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Dan Benjamin TelemanChief Executive Officer | 163.5K | – | Jun 17, 2026 | Form 4 |
A lower bound: it counts only the 1 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 2
- Q4 2025: Managers 2
- Q1 2026: Managers 9
- Q2 2026: Managers 10
Q2 2026: 10 managers held 2.15M shares, worth $7.5M. During the quarter 4 opened a position, 3 closed one, 1 added and 1 trimmed.
The largest holders, Q2 2026
- Balyasny Asset ManagementIn the quarter
- Cable Car CapitalIn the quarter+2.3%
- Velan Capital Investment ManagementIn the quarter
- Hudson Bay Capital ManagementIn the quarter
- BleichroederIn the quarter
- Citadel Advisors (Griffin)In the quarter
- XTX TopcoIn the quarter
- Renaissance TechnologiesIn the quarter
- Morgan StanleyIn the quarter-50%
- Caitong International Asset ManagementIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Balyasny Asset Management | 898.5K | $3.1M | |
| Cable Car Capital | 616.1K | +2.3% | $2.2M |
| Velan Capital Investment Management | 359.4K | $1.3M | |
| Hudson Bay Capital Management | 134.8K | $471.7K | |
| Bleichroeder | 89.8K | $314.5K | |
| Citadel Advisors (Griffin) | 22.0K | $77.0K | |
| XTX Topco | 16.6K | $58.2K | |
| Renaissance Technologies | 12.2K | $42.7K | |
| Morgan Stanley | 1,000 | -50% | $3.5K |
| Caitong International Asset Management | 4 | $14 |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Nasus Pharma's filings show?
Who buys and sells is one part of Nasus Pharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have NSRX's insiders bought or sold?
From Jun 22, 2026 to Nov 16, 2026 Nasus Pharma's insiders bought $20.3K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold NSRX?
2 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $100.0K.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.